AbCellera Biologics Inc

NASDAQ:ABCL  
15.53
-0.38 (-2.39%)
5:02:27 PM EDT: $15.70 +0.17 (+1.10%)
Products, Strategic Combinations

Abcellera And Everest Medicines Announce Multi-Target Collaboration

Published: 09/22/2021 22:09 GMT
AbCellera Biologics Inc (ABCL) - Abcellera and Everest Medicines Announce Multi-target Collaboration to Advance New Antibody Therapies.
Abcellera - 10-target Partnership Leverages Co's Technology to Accelerate Everest's Pipeline of Novel, Innovative Medicines to Patients.
Abcellera Biologics Inc - Everest Will Have Rights to Develop and Commercialize Antibodies Resulting From Collaboration.
Abcellera Biologics Inc - Will Receive Research Payments and is Eligible to Receive From Everest Milestone Payments and Royalties on Sales of Products.